SCYNEXIS Inc. Stock
€1.32
Your prediction
SCYNEXIS Inc. Stock
Pros and Cons of SCYNEXIS Inc. in the next few years
Pros
Cons
Performance of SCYNEXIS Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| SCYNEXIS Inc. | -1.420% | -12.117% | -4.899% | -54.246% | -32.722% | -79.567% | - |
| Avid Bioservices Inc | -4.690% | -4.688% | -4.688% | -64.535% | 0.000% | -61.635% | 60.126% |
| Rockwell Medical Inc. | -3.210% | -8.083% | 5.199% | -29.436% | -22.783% | -83.573% | -96.962% |
| Gritstone Oncology Inc | -5.220% | -12.658% | -72.289% | -71.310% | -62.863% | -90.561% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance at the financials of SCYNEXIS (SCYX), a pharmaceutical company, it is evident that the company has experienced some change in its financial circumstances in recent years. In taking a closer look at the data, there are definite strengths and weaknesses that stand out which would be helpful to consider while forming an opinion on the company's financial performance.
There are some positive aspects to consider of SCYNEXIS's financial performance:
Growing revenue: The company shows an increase in revenue from 2020 to 2021 ($0 to $13,163,000), and a further increase in the quarterly income statement for 2022-12-31 ($1,524,000). This growth trend in revenue may indicate that the company is successfully commercializing its products or services.
Comments
